Netherlands Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Netherlands Pharmaceuticals and Healthcare Report

Netherlands Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Netherlands Pharmaceuticals and Healthcare Report
Published Oct 22, 2016
95 pages — Published Oct 22, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

In August ----, the Minister of Public Health and Dutch centre for stem cell donors, Matchis, launched a campaign to recruit new stem cell donors, addressing the Netherlands current shortage for the treatment of leukaemia and other blood cancers. Data published in the European Heart Journal in August ----, revealed that cardiovascular disease in -- European countries (including the Netherlands) now accounts for far fewer deaths than cancer in men, owing to improvements in prevention and treatments. ...In August ----, the Minister of Public Health and Dutch centre for stem cell donors, Matchis, launched a campaign to recruit new stem cell donors, addressing the Netherlands current shortage for the treatment of leukaemia and other blood cancers. Data published in the European Heart Journal in August ----, revealed that cardiovascular disease in -- European countries (including the Netherlands) now accounts for far fewer deaths than cancer in men, owing to improvements in prevention and treatments. In July ----, Zambon and its partner Newron Pharmaceuticals launched Xadago (safinamide) in the Netherlands for the treatment of mid- to late-stage Parkinson s disease. In June ----, the Dutch minister of health proposed a change in the current abortion legislation, by limiting the period of time in which doctors can carry out the medical procedure. Mylan achieved total revenues in Q---, ended June --, worth USD-,---.-mn, up by -.- over the

...Government cost-cutting measures will continue to depress pricing margins, particularly in the generic drug market. Tightening operating environment to threaten the country s already small number of multinational manufacturing plants. ...Difficulties and delays in getting reimbursement for expensive novel treatments, with the no cure, no pay being the latest measure to target patented drugs. Low rate of economic growth in the short-term could negatively affect the development of the pharmaceuticals market and the over-the-counter segment in particular. The government s social insurance reform is likely to cap growth, while insurers continue to include cheaper generic medicines under their preference policies. ...Low rate of economic growth in the short-term could negatively affect the development of the pharmaceuticals market and the over-the-counter segment in particular. The government s social insurance reform is likely to cap growth, while insurers continue to include cheaper generic medicines under their preference policies.

...Government cost-cutting initiatives, which have tightened criteria for the reimbursement system. Drastic price cuts and agreements not to raise branded drug prices have reduced the market s value in the past. ...

  
Source:
Document ID
1748-2054
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Netherlands Pharmaceuticals and Healthcare Report" Oct 22, 2016. Alacra Store. Dec 07, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Netherlands-Pharmaceuticals-and-Healthcare-Report-2026-295>
  
APA:
Business Monitor International - Industry Reports. (2016). Netherlands Pharmaceuticals and Healthcare Report Oct 22, 2016. New York, NY: Alacra Store. Retrieved Dec 07, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Netherlands-Pharmaceuticals-and-Healthcare-Report-2026-295>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.